Summit Therapeutics Inc. (SMMT)
- Previous Close
3.5900 - Open
3.5200 - Bid 3.5500 x 1000
- Ask 3.5800 x 500
- Day's Range
3.4400 - 3.6150 - 52 Week Range
1.3000 - 5.2200 - Volume
1,366,145 - Avg. Volume
2,165,620 - Market Cap (intraday)
2.491B - Beta (5Y Monthly) -1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9900 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
www.summittxinc.comRecent News: SMMT
Performance Overview: SMMT
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SMMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SMMT
Valuation Measures
Market Cap
2.49B
Enterprise Value
2.41B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
32.06
Enterprise Value/Revenue
6.43k
Enterprise Value/EBITDA
-4.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.79%
Return on Equity (ttm)
-601.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-614.93M
Diluted EPS (ttm)
-0.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
186.24M
Total Debt/Equity (mrq)
136.56%
Levered Free Cash Flow (ttm)
-219.82M